Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Neuromuscular and peripheral nerve disorders

The anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse model.

Qi-Liang Mao-Ying; Annemieke Kavelaars; Karen Krukowski; Xiao-Jiao Huo; Wenjun Zhou; Theodore J Price; Charles Cleeland; Cobi J Heijnen

Originally published in PloS one · 2014-06-23

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) characterized by loss of sensory sensitivity and pain in hands and feet is the major dose-limiting toxicity of many chemotherapeutics. At present, there are no FDA-approved treatments for CIPN. The anti-diabetic drug metformin is the most widely used prescription drug in the world and improves glycemic control in diabetes patients. There is some evidence that metformin enhances the efficacy of cancer treatment. The aim of this study was to test the hypothesis that metformin protects against chemotherapy-induced neuropathic pain and sensory deficits. Mice were treated with cisplatin together with metformin or saline. Cisplatin induced increased sensitivity to mechanical stimulation (mechanical allodynia) as measured using the von Frey test. Co-administration of metformin almost completely prevented the cisplatin-induced mechanical allodynia. Co-administration of metformin also prevented paclitaxel-induced mechanical allodynia. The capacity of the mice to detect an adhesive patch on their hind paw was used as a novel indicator of chemotherapy-induced sensory deficits.

Discussion

The AMP kinase agonist metformin is an anti-diabetic drug that has been safely and widely used for the treatment of type 2 diabetes for decades. This is the first study to show that metformin protects against cisplatin- and paclitaxel-induced mechanical allodynia in a mouse model. Additionally, this is the first study to demonstrate a loss of sensory sensitivity associated with CIPN in a mouse model. We show that cisplatin increases the time to detect an adhesive patch on the hind paw and that metformin prevents development of this sign of sensory impairment or ‘numbness’ in cisplatin-treated mice.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?